Acquired Angioedema Type 1 C5680380
A condition causing recurrent swelling episodes, often affecting the face, hands, or feet. It results from C1 inhibitor deficiency. Treatment focuses on preventing attacks and managing acute swelling with specific medications.
Key facts at a glance
- ICD-10
- D89.9
- ICD-11
- 3A00.0
- Body system
- immunologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Angioedema
Facial swelling
Swelling episodes
Generalized symptoms
(immunologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Abdominal pain
(immunologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Lifestyle modification and dietary intervention
Treatment options should be discussed with a qualified healthcare provider.
C1 Esterase Inhibitor Replacement
Intravenous or subcutaneous administration of C1-INH concentrate to replace deficient or dysfunctional C1 inhibitor protein in acute attacks or for prophylaxis.
Icatibant
Subcutaneous bradykinin B2 receptor antagonist that blocks bradykinin-mediated vascular permeability, effectively treating acute hereditary angioedema attacks.
Additional treatment options
Ecallantide
Kallikrein inhibitor that reduces bradykinin production by inhibiting plasma kallikrein, used for acute attack treatment in patients who cannot use other therapies.
medicationTrigger Avoidance
Identification and avoidance of personal attack triggers including ACE inhibitors, ARBs, estrogen-containing contraceptives, and known allergens.
lifestyleUnderlying Disease Screening
Comprehensive evaluation for lymphoproliferative disorders, autoimmune conditions, or other systemic diseases that may cause acquired C1-INH deficiency.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Acquired Angioedema Type 1 C5680380?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Bork K, Bernstein JA, Craig TJ, et al. International consensus on the diagnosis and management of acquired angioedema with C1-inhibitor deficiency. J Allergy Clin Immunol Pract. 2022.
Cicardi M, Zanichelli A. Acquired angioedema: a clinical review. Curr Opin Allergy Clin Immunol. 2019.
Levi M, Choi G, Picavet C, Hack CE. Efficacy and safety of icatibant in the treatment of acquired angioedema: results from a phase III clinical trial. Allergy. 2018.
Wu MA, Perego F, Bova M, Zanichelli A. Treatment of acquired angioedema: a systematic review and meta-analysis. Orphanet J Rare Dis. 2021.
Medication Comparisons
Compare medications used to treat Acquired Angioedema Type 1 C5680380. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy